Request to Join
has invited you to join this group
Dr. Zain Kassam is the Chief Medical Officer at OpenBiome. He is a gastroenterologist, internal medicine physician and epidemiologist. Zain was named a Top 40 Under 40 Healthcare Innovator by MedTech and is a Scientific Advisory Board member for the American Gastroenterological Association Center for Gut Microbiome Research & Education. Dr. Kassam's research focuses on innovative microbiome-directed therapies that deeply impact human health and disease. He has authored over 100 peer-reviewed abstracts, publications and book chapters and holds grants from the CDC, CCFA and private foundations. Dr. Kassam received his MPH degree with a focus on Clinical Trials at Harvard University on a Frank Knox Fellowship and completed his post-doctoral training in microbiome engineering at MIT. He completed both his Internal Medicine and Gastroenterology training at McMaster University, where he was the Chief Medical and Chief Gastroenterology Resident and was awarded the National Resident Leadership Award by the Royal College of Physicians and Surgeons of Canada.
Dr. Kelly is a gastroenterologist at the Lifespan Women’s Medicine Collaborative and an Assistant Professor of Medicine at The Alpert Medical School of Brown University. She graduated from The Ohio State University College of Medicine in Columbus, Ohio in 1999 and completed residency in internal medicine at Boston Medical Center and GI fellowship at the Rhode Island Hospital/Brown program. The focus of her research and clinical practice is fecal microbiota transplantation (FMT) for the treatment of C. difficile infection (CDI). Dr. Kelly was the principal investigator (PI) for a recently published randomized controlled trial of FMT for treatment of recurrent CDI. She was one of the first investigators to sponsor of an investigational new drug (IND) application with the FDA to conduct this trial and has served on working groups focusing on regulatory issues related to FMT. She is currently one of the PIs for an NIH-funded fecal transplant national registry which will answer important questions around real- world efficacy and safety of FMT. Dr. Kelly has assisted other physicians and institutions around the country in developing FMT protocols and collaborates regionally, nationally and internationally with other physicians and scientists who have clinical and research interests in FMT with the goal of moving this novel treatment forward. She participates in industry-sponsored clinical trials of microbiota-based therapeutics for CDI and is co-investigator on several other projects looking at FMT in other conditions associated with dysbiosis. In addition to coauthoring current FMT guidelines, she has published numerous other papers and abstracts and regularly lectures nationally on this subject. She is a member of the Women in GI Committee for the American College of Gastroenterology and is also a past member of the scientific advisory board for the American Gastroenterological Association Center for Gut Microbiome Research and Education.
Dr. Jessica Allegretti is an attending gastroenterologist at the Brigham and Women’s Hospital Crohn’s and Colitis Center, where she serves as the center’s Director of Clinical Trials as well as the hospital’s Fecal Transplant Program Director. Dr. Allegretti’s research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases, specifically clostridium difficile infections (CDI) and inflammatory bowel disease (IBD). Additionally she is leading several clinical trials investigating the role of FMT in other chronic diseases including obesity and primary sclerosis cholangitis (PSC).
Dr Aïda Bafeta is a post-doctoral researcher at the INSERM – Sorbonne Paris Cité Epidemiology and Statistics Research Centre (UMR 1153) in the METHODS team. Her focus is on methodological problem of evaluation of clinical intervention using microbiota. Her research interests are primarily on the conduct and reporting of studies, the interpretation of results of studies, systematic review and meta-analysis. She has also worked on characteristics of studies that may have an impact on the estimation of treatment effect.